Researchers have suspected for some time that the link between our gut and brain plays a role in the development of Parkinson ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

This fall, the Montreal Neurological Institute and Hospital (The Neuro, at McGill University and the McGill University Health Centre) expects to introduce a previously unavailable form of treatment ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease ... patients may be more prone to treatment-emergent adverse ...

A medical device company developing technology to improve outcomes for stroke patients will begin enrollment for a new ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...